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A BS TR AC T
BACKGROUND
In phase 2 studies, treatment with the all-oral combination of the nucleotide poly-
merase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates 
of sustained virologic response among previously untreated patients with hepatitis C 
virus (HCV) genotype 1 infection.
METHODS
We conducted a phase 3, open-label study involving previously untreated patients 
with chronic HCV genotype 1 infection. Patients were randomly assigned in a 
1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet 
once daily for 12 weeks, ledipasvir–sofosbuvir plus ribavirin for 12 weeks, ledipas-
vir–sofosbuvir for 24 weeks, or ledipasvir–sofosbuvir plus ribavirin for 24 weeks. 
The primary end point was a sustained virologic response at 12 weeks after the end 
of therapy.
RESULTS
Of the 865 patients who underwent randomization and were treated, 16% had cir-
rhosis, 12% were black, and 67% had HCV genotype 1a infection. The rates of 
sustained virologic response were 99% (95% confidence interval [CI], 96 to 100) in 
the group that received 12 weeks of ledipasvir–sofosbuvir; 97% (95% CI, 94 to 99) 
in the group that received 12 weeks of ledipasvir–sofosbuvir plus ribavirin; 98% 
(95% CI, 95 to 99) in the group that received 24 weeks of ledipasvir–sofosbuvir; and 
99% (95% CI, 97 to 100) in the group that received 24 weeks of ledipasvir–sofosbuvir 
plus ribavirin. No patient in either 12-week group discontinued ledipasvir–sofosbuvir 
owing to an adverse event. The most common adverse events were fatigue, head-
ache, insomnia, and nausea.
CONCLUSIONS
Once-daily ledipasvir–sofosbuvir with or without ribavirin for 12 or 24 weeks was 
highly effective in previously untreated patients with HCV genotype 1 infection. 
(Funded by Gilead Sciences; ION-1 ClinicalTrials.gov number NCT01701401.)
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A lthough the treatment of pa-tients infected with the hepatitis C virus (HCV) has evolved greatly in recent years, 
newly approved regimens for the treatment of pa-
tients with HCV genotype 1 infection still include 
weekly injections of recombinant human inter-
feron alfa and ribavirin administered according 
to body weight.1-3 The only interferon-free option 
currently approved by the Food and Drug Admin-
istration for the treatment of HCV genotype 1 
infection is 24 weeks of sofosbuvir and ribavirin 
for patients who are ineligible to receive interferon; 
the reported response rate is 68%.4
Interferon treatment is associated with a num-
ber of side effects, including influenza-like symp-
toms, depression, and cytopenia.5,6 The side effects 
of ribavirin include hemolytic anemia, fatigue, 
pruritus, and rash.7 The elimination of interferon 
and ribavirin from treatment regimens is expect-
ed to reduce the incidence and severity of adverse 
events, to simplify the treatment of patients with 
HCV infection, and to provide a treatment op-
tion for patients who are ineligible for treatment 
with interferon or ribavirin. Treatment guide-
lines recently issued by the American Associa-
tion for the Study of Liver Diseases and the In-
fectious Diseases Society of America recommend 
interferon-free combinations of newly approved 
direct-acting antiviral agents, but the supporting 
data are from small, phase 2 studies.8
Ledipasvir (Gilead Sciences) is a new HCV NS5A 
inhibitor with potent antiviral activity against 
HCV genotypes 1a and 1b.9 Sofosbuvir is a nucle-
otide polymerase inhibitor approved for the treat-
ment of HCV genotypes 1 through 4 in combina-
tion with ribavirin, with or without peginterferon.1 
In phase 2 trials, the combination of ledipasvir 
and sofosbuvir with or without ribavirin resulted 
in high rates of sustained virologic response 
among previously untreated patients with HCV 
genotype 1 infection, including those with com-
pensated cirrhosis.10,11 In the ION-2 phase 3 
trial, previously treated patients, including those 
with cirrhosis, had rates of sustained virologic 
response of 94 to 99% after 12 or 24 weeks of 
treatment with ledipasvir–sofosbuvir, with or 
without ribavirin.12 We conducted the ION-1 
phase 3 trial to assess the efficacy and safety of 
12 or 24 weeks of a fixed-dose combination of 
ledipasvir and sofosbuvir, with or without riba-
virin (Ribasphere, Kadmon Pharmaceuticals), in 
previously untreated patients with chronic HCV 
genotype 1 infection, including those with com-
pensated cirrhosis.
ME THODS
PATIENTS
We enrolled patients at 99 sites in the United 
States and Europe from October 17, 2012, to May 
17, 2013. Eligible patients were 18 years of age or 
older, had chronic HCV genotype 1 infection, 
and had not received treatment for HCV infection 
previously. There were no upper limits for age or 
body-mass index. The protocol (available with 
the full text of this article at NEJM.org) specified 
that patients with cirrhosis could account for ap-
proximately 20% of the study population. The 
presence of cirrhosis was defined as a liver-biopsy 
specimen showing evidence of cirrhosis (Metavir 
stage F4 [on a scale of F0 to F4, with higher stages 
indicating a greater degree of fibrosis] or Ishak 
score of 5 or 6 [on a scale of 0 to 6, with higher 
scores indicating a greater degree of fibrosis]), a 
FibroScan score of more than 12.5 kPa (on a scale 
of 1.5 to 75.0 kPa, with higher scores indicating 
a greater degree of fibrosis), or a FibroTest score 
of more than 0.75 (on a scale of 0 to 1, with high-
er scores indicating more severe fibrosis) and an 
aspartate aminotransferase:platelet ratio index of 
more than 2 (with higher scores indicating a 
greater likelihood of extensive fibrosis). The full 
set of eligibility criteria, including details of the 
assessment of cirrhosis, are provided in the study 
protocol.
STUDY DESIGN
In this multicenter, randomized, open-label trial, 
all the patients received a fixed-dose combination 
tablet containing 90 mg of ledipasvir and 400 mg 
of sofosbuvir, administered orally once daily. Rib-
avirin was administered orally twice daily, with 
the dose determined according to body weight 
(1000 mg daily in patients with a body weight 
<75 kg, and 1200 mg daily in patients with a 
body weight ≥75 kg).
Patients were randomly assigned in a 1:1:1:1 
ratio to one of four treatment groups: ledipasvir–
sofosbuvir for 12 weeks, ledipasvir–sofosbuvir 
plus ribavirin for 12 weeks, ledipasvir–sofosbu-
vir for 24 weeks, or ledipasvir–sofosbuvir plus 
ribavirin for 24 weeks. Enrollment occurred in 
two phases. First, 200 patients underwent random-
ization and were treated. After patients in the 
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12-week groups reached post-treatment week 4, 
the data and safety monitoring committee re-
viewed safety data collected during treatment for 
all four groups and response data at post-treat-
ment week 4 in the 12-week groups. A planned 
interim analysis indicated that the rate of sus-
tained virologic response at 4 weeks after the 
end of treatment was more than 60%, and there-
fore the prespecified criteria for futility were not 
met (see the Supplementary Appendix, available 
at NEJM.org), and an additional 665 patients were 
randomly assigned to the four treatment groups. 
Randomization was stratified according to HCV 
genotype 1 subtype (1a or 1b) and the presence 
or absence of cirrhosis.
STUDY OVERSIGHT
This study was approved by the institutional re-
view board or independent ethics committee at 
each participating site and was conducted in com-
pliance with the principles of the Declaration of 
Helsinki, Good Clinical Practice guidelines, and 
local regulatory requirements. The study was de-
signed and conducted according to the protocol 
by the sponsor (Gilead Sciences) in collaboration 
with the principal investigators. The sponsor col-
lected the data, monitored the study conduct, 
and performed the statistical analyses. An inde-
pendent data and safety monitoring committee 
reviewed the progress of the study.
The investigators, participating institutions, 
and sponsor agreed to maintain confidentiality 
of the data. All the authors had access to the 
data and assume responsibility for the integrity 
and completeness of the reported data. All the 
authors affirm that the study was conducted 
with fidelity to the protocol. The first draft of 
the manuscript was prepared by a professional 
writer who is an employee of the sponsor and by 
the first author, with input from all coauthors.
STUDY ASSESSMENTS
Screening assessments included measurement of 
the serum HCV RNA level and IL28B genotyping, 
in addition to standard laboratory and clinical 
tests. The serum HCV RNA level was measured 
with the use of the COBAS TaqMan HCV Test, 
version 2.0, for use with the High Pure System 
(Roche Molecular Systems), which has a lower 
limit of quantification of 25 IU per milliliter. 
HCV genotype and subtype were determined with 
the use of the Versant HCV Genotype INNO-LiPA 
2.0 assay (Siemens Healthcare Diagnostics). IL28B 
genotype was determined by means of polymerase-
chain-reaction amplification and sequencing of 
the rs12979860 single-nucleotide polymorphism.
Assessments during treatment included stan-
dard laboratory testing, measurement of the se-
rum HCV RNA level, assessment of vital signs, 
electrocardiography, and symptom-directed phys-
ical examinations. All adverse events were re-
corded and graded according to a standardized 
scale (see the study protocol).
Population sequencing or deep sequencing of 
the NS5A and NS5B regions of the HCV RNA 
was performed for all the patients at baseline. 
For all the patients who had virologic failure, 
deep sequencing of the NS5A and NS5B regions 
was conducted at baseline and at the time of fail-
ure. The sequences obtained at the time of viro-
logic failure were compared with sequences 
from baseline samples and references in order to 
detect resistance-associated variants that emerged 
during treatment. We report resistance-associated 
variants that were present in more than 1% of 
the sequence reads.
END POINTS
The primary efficacy end point was a sustained 
virologic response at 12 weeks after the end of 
treatment. It was assessed in all the patients who 
underwent randomization and received treatment.
STATISTICAL ANALYSIS
In the primary efficacy analysis, the rate of sus-
tained virologic response in each of the treat-
ment groups was compared with an adjusted his-
torical rate of 60%, with the use of a two-sided 
exact one-sample binomial test. This 60% rate 
was based on calculated rates of sustained viro-
logic response of 65% in phase 3 trials of telapre-
vir13 and boceprevir,14 allowing for a rate that 
was 5 percentage points lower, in exchange for 
an expected improved safety profile and shorter 
duration of treatment. The weighted average rates 
of response in the telaprevir and boceprevir trials 
were estimated to be approximately 70% among 
patients without cirrhosis and 44% among those 
with cirrhosis (see the Supplementary Appendix 
for details on the calculation of the control rate). 
We determined that a sample of 200 patients in 
each treatment group would provide the study 
with more than 91% power to detect an improve-
ment of at least 13 percentage points in the rate 
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of sustained virologic response from the adjust-
ed historical null rate of 60%, with the use of a 
two-sided, exact one-sample binomial test at a 
significance level of 0.0125, based on a Bonfer-
roni correction. The two-sided 95% exact confi-
dence interval calculated by the Clopper–Pear-
son method is provided for the rate of sustained 
virologic response at 12 weeks after the end of 
treatment in each of the four treatment groups.
R ESULT S
BASELINE CHARACTERISTICS
Of the 1015 patients who were initially screened, 
870 underwent randomization, and 865 began 
treatment (Table S1 and Fig. S1 in the Supple-
mentary Appendix). A total of 5 patients under-
went randomization but were not treated owing 
to withdrawal of consent (4 patients) or errone-
ous randomization (1 patient). The demographic 
and baseline clinical characteristics of the pa-
tients were generally balanced among the four 
treatment groups, except that the two treatment 
groups that received ribavirin had higher propor-
tions of patients with the CC allele of IL28B than 
did the groups that received ledipasvir–sofosbu-
vir alone (Table 1).
Overall, 67% of the patients had HCV geno-
type 1a infection, 12% were black, 70% had the 
non-CC IL28B genotype, 16% had cirrhosis, 3% 
had a platelet count of less than 90,000 per cubic 
millimeter, and 4% had an albumin level of less 
than 3.5 g per deciliter. A total of seven patients 
had both a platelet count of less than 90,000 per 
cubic millimeter and an albumin level of less 
than 3.5 g per deciliter. A total of 19% of the 
patients had a history of depression, 14% had 
insomnia, 12% had anxiety, and 9% had a his-
tory of diabetes mellitus or were taking medica-
tion for diabetes. Approximately 41% of the pa-
tients were enrolled in Europe.
EFFICACY
The rates of sustained virologic response in all 
four treatment groups were superior to the his-
torical rate of 60% (P<0.001 for all comparisons). 
The rates of sustained virologic response 12 weeks 
after the end of treatment were as follows: among 
214 patients who received 12 weeks of ledipas-
vir–sofosbuvir, 211 had a sustained virologic re-
sponse (99%; 95% confidence interval [CI], 96 to 
100); among 217 who received 12 weeks of ledi-
pasvir–sofosbuvir plus ribavirin, 211 had a sus-
tained virologic response (97%; 95% CI, 94 to 99); 
among 217 who received 24 weeks of ledipasvir–
sofosbuvir, 212 had a sustained virologic response 
(98%; 95% CI, 95 to 99); and among 217 who 
received 24 weeks of ledipasvir–sofosbuvir plus 
ribavirin, 215 had a sustained virologic response 
(99%; 95% CI, 97 to 100) (Table 2).
Of the 865 patients who underwent random-
ization and were treated, only 3 had virologic 
failure. A total of 1 patient who received 24 weeks 
of ledipasvir–sofosbuvir had virologic break-
through during treatment. This patient, a 
63-year-old black man with HCV genotype 1b 
infection, had plasma concentrations of ledipas-
vir and GS-331007 (the main circulating metabo-
lite of sofosbuvir) that were below the level of 
quantification at both weeks 8 and 10, which 
strongly suggests nonadherence to the study regi-
men. A total of 2 patients had virologic relapse 
after finishing treatment: a 56-year-old white 
man with cirrhosis and HCV genotype 1a infec-
tion who received 12 weeks of ledipasvir–sofos-
buvir had a relapse by post-treatment week 4, 
and a 65-year-old black man with cirrhosis and 
HCV genotype 1b infection who received 24 weeks 
of ledipasvir–sofosbuvir had a relapse between 
post-treatment weeks 4 and 12.
Given the very high levels of sustained viro-
logic response observed overall, high response 
rates were observed in all patient subgroups, 
including patients with characteristics histori-
cally associated with a poor response to treat-
ment, who had response rates similar to those 
among patients without these characteristics 
(Fig. 1). According to the intention-to-treat anal-
ysis, the rates of sustained virologic response in 
the four treatment groups ranged from 94 to 
100% among patients with cirrhosis, 97 to 99% 
among those with HCV genotype 1a infection, 
97 to 99% among those with a non-CC IL28B 
allele, and 91 to 100% among black patients 
(Fig. S2 in the Supplementary Appendix). Of the 
seven patients with both an albumin level of less 
than 3.5 g per deciliter and a platelet count of 
less than 90,000 per cubic millimeter at baseline, 
six had a sustained virologic response; the other 
patient withdrew consent after having received 
only a single dose of ledipasvir–sofosbuvir.
VIROLOGIC RESISTANCE TESTING
At baseline, variants associated with resistance 
to NS5A inhibitors were detected in 92 of 861 
patients (11%) and were confirmed by means of 
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic 12-Wk Regimen 24-Wk Regimen
LDV–SOF
(N = 214)
LDV–SOF + RBV  
(N = 217)
LDV–SOF  
(N = 217)
LDV–SOF + RBV  
(N = 217)
Age — yr
Mean 52 52 53 53
Range 18–75 18–78 22–80 24–77
Body-mass index†
Mean 27 27 27 26
Range 18–41 18–42 18–48 18–48
Male sex — no. (%) 127 (59) 128 (59) 139 (64) 119 (55)
Race — no. (%)‡
White 187 (87) 188 (87) 177 (82) 183 (84)
Black 24 (11) 26 (12) 32 (15) 26 (12)
Asian 1 (<1) 0 5 (2) 5 (2)
Other 2 (1) 3 (1) 3 (1) 3 (1)
Ethnic group — no. (%)§
Hispanic 26 (12) 20 (9) 29 (13) 26 (12)
Non-Hispanic 187 (87) 197 (91) 188 (87) 190 (88)
Region — no. (%)
United States 125 (58) 118 (54) 132 (61) 137 (63)
Europe 89 (42) 99 (46) 85 (39) 80 (37)
HCV genotype — no. (%)
1a 144 (67) 148 (68) 146 (67) 143 (66)
1b 66 (31) 68 (31) 68 (31) 71 (33)
Other ¶ 4 (2) 1 (<1) 3 (1) 3 (1)
HCV RNA — log10 IU/ml 6.4±0.69 6.4±0.64 6.3±0.68 6.3±0.65
HCV RNA ≥800,000 IU/ml — no. (%) 169 (79) 173 (80) 168 (77) 173 (80)
IL28B genotype — no. (%)
CC 55 (26) 76 (35) 52 (24) 73 (34)
CT 113 (53) 107 (49) 119 (55) 112 (52)
TT 46 (21) 34 (16) 46 (21) 32 (15)
Cirrhosis — no. (%) 34 (16) 33 (15) 33 (15) 36 (17)
Albumin <3.5 g/dl — no. (%) 6 (3) 6 (3) 11 (5) 12 (6)
Platelet count <90,000 per mm3 — no. (%) 5 (2) 6 (3) 8 (4) 4 (2)
Alanine aminotransferase >1.5× ULN — no. (%) 120 (56) 119 (55) 109 (50) 112 (52)
Interferon eligibility status — no. (%)
Eligible 200 (93) 197 (91) 198 (91) 203 (94)
Ineligible 14 (7) 20 (9) 19 (9) 14 (6)
* Plus–minus values are means ±SD. No significant between-group differences in demographic or clinical variables were 
observed. HCV denotes hepatitis C virus, LDV ledipasvir, RBV ribavirin, SOF sofosbuvir, and ULN upper limit of the 
normal range.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Race was self-reported.
§ Ethnic group was self-reported. Two patients did not report ethnic group (one patient in the group that received 12 weeks 
of ledipasvir–sofosbuvir, and one in the group that received 24 weeks of ledipasvir–sofosbuvir and ribavirin).
¶ Patients with an HCV genotype that was not classified as HCV genotype 1a or 1b included four patients with an uncon-
firmed HCV genotype (one patient in each treatment group), two with HCV genotype 4 (one in the 12-week group that 
received ledipasvir–sofosbuvir and one in the 24-week group that received ledipasvir–sofosbuvir plus ribavirin), and five 
with missing data (two in the 12-week group that received ledipasvir–sofosbuvir, two in the 24-week group that received 
ledipasvir–sofosbuvir, and one in the 24-week group that received ledipasvir–sofosbuvir plus ribavirin). 
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deep sequencing in 140 of 861 patients (16%), 
135 of whom (96%) had a sustained virologic 
response. Of the 3 patients who had virologic 
failure, the 2 with relapses had NS5A-resistant 
variants at baseline, whereas the patient with 
virologic breakthrough did not. All three sam-
ples obtained at the time of virologic failure had 
NS5A-resistant variants; the patient with HCV 
genotype 1a infection had the L31M variant, 
and both patients with HCV genotype 1b infec-
tion had the Y93H variant. Neither of the two 
samples from patients with relapse showed 
 evidence of mutations conferring resistance to 
sofosbuvir (Table S4 in the Supplementary Ap-
pendix).
SAFETY
Of the 865 patients who underwent randomiza-
tion and were treated, 10 discontinued ledipas-
vir–sofosbuvir prematurely owing to adverse 
events: 4 patients (2%) in the group that received 
ledipasvir–sofosbuvir for 24 weeks, and 6 (3%) in 
the group that received ledipasvir–sofosbuvir 
plus ribavirin for 24 weeks (Table 3). All 10 of 
these patients had a sustained virologic response; 
the shortest duration of therapy among these pa-
tients was 8 weeks. No patient who received ledi-
pasvir–sofosbuvir for 12 weeks discontinued 
treatment early (Table S6 in the Supplementary 
Appendix).
Of the 33 patients who had a serious adverse 
event during treatment, 25 were in the 24-week 
groups (18 patients who received ledipasvir–sofos-
buvir and 7 who received ledipasvir–sofosbuvir 
plus ribavirin) and 8 were in the 12-week groups 
(1 who received ledipasvir–sofosbuvir and 7 who 
received ledipasvir–sofosbuvir plus ribavirin). 
Six serious adverse events occurred in more than 
1 patient: cellulitis, chest pain, gastroenteritis, 
hand fracture, noncardiac chest pain, and pneu-
monia each occurred in 2 patients (Table S5 in 
the Supplementary Appendix).
The majority of patients in all the treatment 
groups (79 to 92%) had at least one adverse 
event. Of the patients who had adverse events, 
93% had only events that were mild to moderate 
in severity (Table 3). The most common adverse 
events were fatigue, headache, insomnia, and 
nausea. Patients in the groups that received ledi-
pasvir–sofosbuvir plus ribavirin for 12 or 24 
weeks had higher rates of events known to be 
associated with ribavirin therapy — fatigue, in-
somnia, asthenia, rash, cough, pruritus, and 
anemia — than did those in the corresponding 
groups that received ledipasvir–sofosbuvir with-
out ribavirin (Table 3).
Patients who received 12 or 24 weeks of ledi-
pasvir–sofosbuvir alone had mean changes (from 
baseline to the end of treatment) in the hemo-
globin level of −0.4 g per deciliter and −0.2 g per 
Table 2. Response during and after Treatment.
Response 12-Wk Regimen 24-Wk Regimen
LDV–SOF
(N = 214)
LDV–SOF + RBV  
(N = 217)
LDV–SOF  
(N = 217)
LDV–SOF + RBV  
(N = 217)
HCV RNA <25 IU/ml
During treatment — no./total no. (%)*
At week 2 174/213 (82) 181/217 (83) 179/216 (83) 180/217 (83)
At week 4 213/213 (100) 215/217 (99) 216/216 (100) 217/217 (100)
At week 12 213/213 (100) 214/214 (100) 213/214 (>99) 216/216 (100)
After end of treatment — no. (%)
At week 4 211 (99) 213 (98) 215 (99) 215 (99)
At week 12 211 (99) 211 (97) 212 (98) 215 (99)
Virologic failure during treatment — no. 0 0 1 0
Relapse — no. 1 0 1 0
Lost to follow-up — no. 2 4 2 2
Withdrew consent — no. 0 2 1 0
* Data shown are for patients for whom HCV RNA results were available.
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deciliter, respectively; in the patients who re-
ceived 12 or 24 weeks of ledipasvir–sofosbuvir 
plus ribavirin, the mean changes were −2.2 g per 
deciliter and −1.9 g per deciliter, respectively. 
Severe hyperbilirubinemia (bilirubin level of >2.5 
times the upper limit of the normal range) devel-
oped in nine patients (4%) in the 12-week group 
that received ribavirin and in seven (3%) in the 
24-week group that received ribavirin, as com-
pared with hyperbilirubinemia in one patient 
(<1%), who had Gilbert’s syndrome, in the group 
that received 24 weeks of ledipasvir–sofosbuvir 
alone.
DISCUSSION
In this multicenter, randomized, phase 3 study, 
the rates of sustained virologic response in all 
four treatment groups were 97% or higher, re-
gardless of whether the regimen was given for 12 
or 24 weeks and whether it included ribavirin. 
The rates of treatment discontinuation were high-
er in the groups treated for 24 weeks than in the 
groups treated for 12 weeks, and the rates of side 
effects were higher in the groups that received 
ribavirin than in the corresponding groups that 
did not. This trial showed that a 12-week regi-
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Figure 1. Rates of Sustained Virologic Response According to Subgroup.
The position of the square indicates the rate of virologic response at 12 weeks after the end of treatment in each subgroup; the horizontal 
lines indicate 95% confidence intervals. The vertical lines represent the overall rate of sustained virologic response in each treatment group. 
Subgroup results do not include patients who withdrew consent or were lost to follow-up. Figure S2 in the Supplementary Appendix 
shows a forest plot that is based on the full intention-to-treat population. HCV denotes hepatitis C virus, LDV ledipasvir, RBV ribavirin, 
SOF sofosbuvir, and ULN upper limit of the normal range. 
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men of ledipasvir–sofosbuvir, without ribavirin, 
constitutes an effective treatment for patients 
who have HCV genotype 1 infection, with the 
lowest rate of adverse events of the four regimens 
evaluated.
The response to interferon-based regimens 
for HCV infection varies considerably according 
to certain characteristics of patients (e.g., base-
line viral load, race, HCV genotype, IL28B geno-
type, and extent of fibrosis) and the presence or 
absence of an early response during treatment.15 
In this trial, the rates of response were gener-
ally uniform, regardless of the characteristics of 
the patients at baseline. Given the high rates of 
response with 12 weeks of therapy, the possibil-
ity of further reducing the duration of therapy 
was explored in the ION-3 study (also now re-
ported in the Journal).16 ION-3 showed that the 
addition of ribavirin in an 8-week regimen or the 
extension of treatment to 12 weeks did not result 
in better response rates than 8 weeks of ledipas-
vir–sofosbuvir alone.
The rates of response to interferon-based 
therapy, including protease-inhibitor–containing 
regimens, have been low in patients with cirrho-
sis.13-15,17-19 For the protease-inhibitor–containing 
regimens, 48 weeks of treatment is recommended 
for all such patients; response-guided shorten-
ing of the duration of therapy has been associ-
ated with an unacceptable rate of relapse.13 The 
low rates of response among patients with cir-
rhosis reflect both an increased risk of inter-
Table 3. Treatment Discontinuations, Adverse Events, and Hematologic Abnormalities.*
Variable 12-Wk Regimen 24-Wk Regimen
LDV–SOF
(N = 214)
LDV–SOF + RBV  
(N = 217)
LDV–SOF  
(N = 217)
LDV–SOF + RBV  
(N = 217)
Duration of treatment — wk 12.1±0.8 12.0±0.7 23.6±2.6 23.7±1.9
Discontinuation of ledipasvir–sofosbuvir owing to 
adverse event — no. of patients (%)
0 0 4 (2) 6 (3)
Serious adverse event — no. of patients (%) 1 (<1) 7 (3) 18 (8) 7 (3)
Any adverse event — no. of patients (%) 169 (79) 185 (85) 178 (82) 200 (92)
Common adverse events — no. of patients (%)†
Fatigue 44 (21) 79 (36) 53 (24) 82 (38)
Headache 53 (25) 49 (23) 54 (25) 65 (30)
Insomnia 17 (8) 45 (21) 26 (12) 47 (22)
Nausea 24 (11) 37 (17) 29 (13) 32 (15)
Asthenia 14 (7) 23 (11) 20 (9) 26 (12)
Diarrhea 24 (11) 18 (8) 24 (11) 14 (6)
Rash 16 (7) 21 (10) 16 (7) 27 (12)
Irritability 11 (5) 17 (8) 17 (8) 24 (11)
Cough 6 (3) 21 (10) 16 (7) 25 (12)
Pruritus 11 (5) 22 (10) 8 (4) 20 (9)
Anemia 0 25 (12) 0 22 (10)
Hematologic abnormality — no. of patients (%)
Decreased hemoglobin level
<10 g/dl 0 20 (9) 0 16 (7)
<8.5 g/dl 0 1 (<1) 0 0
Lymphocyte count <350 per mm3 0 1 (<1) 0 0
Neutrophil count 500 to <750 per mm3 1 (<1) 0 3 (1) 0
Platelet count 25,000 to <50,000 per mm3 1 (<1) 0 1 (<1) 0
* Plus–minus values are means ±SD.
† Common adverse events were those that occurred in at least 10% of the patients in any group.
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feron-related side effects20 and an unidentified 
effect of cirrhosis on responsiveness to treatment. 
The presence of a low platelet count and an al-
bumin level of less than 3.5 g per deciliter have 
been identified as risk factors for adverse events, 
including infection, hepatic decompensation, and 
death. In this study, the presence of cirrhosis 
had no marked effect on rates of response or the 
safety profile, even among patients with throm-
bocytopenia and a low albumin level. This study, 
however, was not designed or powered to for-
mally compare the rates of response among pa-
tients with cirrhosis and those without cirrhosis.
Virologic failure was extremely rare in this 
study population, occurring in only 0.3% of pa-
tients (3 of 865). In these patients, we did not 
discern clinical or virologic predictors of viro-
logic failure except suspected nonadherence to 
therapy, which was documented by means of se-
rum assays for drug levels, in one patient with 
virologic breakthrough during treatment. The two 
patients with relapse had no evidence of muta-
tions conferring resistance to sofosbuvir, although 
both patients had mutations associated with re-
sistance to NS5A inhibitors both at baseline and 
at the time of relapse. A sofosbuvir-based regimen 
with a protease inhibitor would be a potential op-
tion for retreatment in these patients.
There was no control group in this study, and 
we were not able to assess which adverse events 
resulted from ledipasvir–sofosbuvir. The most 
common adverse events included fatigue, head-
ache, insomnia, and nausea. The type, frequen-
cy, and severity of the adverse events observed in 
the groups that received ledipasvir–sofosbuvir 
without ribavirin were generally similar to those 
seen in the placebo group in a previous trial of 
sofosbuvir and ribavirin in patients with HCV 
infection.21 However, the groups receiving ledi-
pasvir–sofosbuvir plus ribavirin in our study had 
a higher incidence of adverse events and labora-
tory abnormalities that are known to be associ-
ated with ribavirin therapy — fatigue, insomnia, 
cough, pruritus, and anemia.6 Thus, our find-
ings suggest that the addition of ribavirin to a 
ledipasvir–sofosbuvir regimen increases toxicity 
without providing additional efficacy.
In conclusion, our study showed that 12 weeks 
of the single-tablet regimen of ledipasvir–sofos-
buvir was a highly effective treatment for a broad 
range of patients with HCV genotype 1 infection 
who had not been treated previously. No addi-
tional benefit appeared to be associated with the 
addition of ribavirin or with extension of the 
duration of treatment to 24 weeks.
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